Recursion Pharmaceuticals (RXRX) Stock Statistics & Valuation Metrics

Recursion Pharmaceuticals has a market cap or net worth of $2.42B. The enterprise value is $1.76B.

Market Cap

$2.42B

Enterprise Value

$1.76B

Recursion Pharmaceuticals has 622,759,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

622,759,300

Owned by Insiders

2.49%

Owned by Institutions

38.00%

Recursion Pharmaceuticals’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -48.06%.

Return on Equity (ROE)

-0.57

Return on Assets (ROA)

-0.44

Return on Invested Capital (ROIC)

-48.06%

Return on Capital Employed (ROCE)

-0.49

Revenue Per Employee

124.47K

Profits Per Employee

-1.07M

Employee Count

600

Asset Turnover

0.05

Inventory Turnover

0.00

The current PE Ratio of Recursion Pharmaceuticals is -3.89. Recursion Pharmaceuticals’s PEG ratio is -0.05.

PE Ratio

-3.89

PS Ratio

31.94

PB Ratio

2.10

Price to FCF

-6.93

Price to Operating Cash Flow

-6.12

PEG Ratio

-0.05

In the last 12 months, Recursion Pharmaceuticals had revenue of 74.68M and earned -644.76M in profits. Earnings per share was -1.44.

Revenue

74.68M

Gross Profit

-46.27M

Operating Income

-648.13M

Pretax Income

-644.89M

Net Income

-644.76M

EBITDA

-559.38M

Earnings Per Share (EPS)

-1.44

In the last 12 months, operating cash flow was -310.53M and capital expenditures -3.95M, giving a free cash flow of -314.48M billion.

Operating Cash Flow

-310.53M

Free Cash Flow

-314.48M

Free Cash Flow per Share

-0.58

Recursion Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-14.51%

Earnings Yield

-25.17%

Beta

3.13

52-Week Price Change

-29.44%

50-Day Moving Average

3.76

200-Day Moving Average

3.49

Relative Strength Index (RSI)

50.10

Average Volume (3m)

22.47M

Recursion Pharmaceuticals upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 02, 2026

Next Earnings Date

Mar 03, 2027

Ex-Dividend Date

―

Recursion Pharmaceuticals as a current ratio of 5.50, with Debt / Equity ratio of 6.89%

Current Ratio

5.50

Quick Ratio

5.50

Debt to Market Cap

0.01

Net Debt to EBITDA

1.19

Interest Coverage Ratio

-358.08

In the past 12 months, Recursion Pharmaceuticals has paid -136.00K in taxes.

Income Tax

-136.00K

Effective Tax Rate

0.00

Recursion Pharmaceuticals EV to EBITDA ratio is -4.17, with an EV/FCF ratio of -5.38.

EV to Sales

24.80

EV to EBITDA

-4.17

EV to Free Cash Flow

-5.38

EV to Operating Cash Flow

-5.45

Recursion Pharmaceuticals has $549.85M in cash and marketable securities with $74.70M in debt, giving a net cash position of $475.15M billion.

Cash & Marketable Securities

$549.85M

Total Debt

$74.70M

Net Cash

$475.15M

Net Cash Per Share

$0.76

Tangible Book Value Per Share

$0.87

Gross margin is 10.74%, with operating margin of -725.44%, and net profit margin of -697.13%.

Gross Margin

10.74%

Operating Margin

-725.44%

Pretax Margin

-703.81%

Net Profit Margin

-697.13%

EBITDA Margin

-594.61%

EBIT Margin

-702.85%

The average price target for Recursion Pharmaceuticals is $6.63, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$6.63

Price Target Upside

89.52% Upside

Analyst Consensus

Moderate Buy

Analyst Count

4

Revenue Growth Forecast

56.18%

EPS Growth Forecast

50.69%

Smart Score

6

AI Score

54